The overall recovery in the software industry has been notable, indicating a potential shift in market dynamics as investors respond to improving conditions in these sectors.
Investors should monitor Moderna's upcoming product announcements and clinical trial results, as these could further influence its stock trajectory. Additionally, keep an eye on how the broader recovery in the software sector may impact investor sentiment across tech stocks.